Session

H. pylori (Posters)

AN EVOLVING RESISTANT PANDEMIC. RISING COMMUNITY H. PYLORI TREATMENT FAILURE TO CLARITHROMYCIN-BASED TRIPLE THERAPY: AN OBSERVATIONAL STUDY
AN EVOLVING RESISTANT PANDEMIC. RISING COMMUNITY H. PYLORI TREATMENT FAILURE TO CLARITHROMYCIN-BASED TRIPLE THERAPY: AN OBSERVATIONAL STUDY

EFFECTIVENESS AND SAFETY OFNOVELVONOPRAZAN-BASED REGIMEN FOR H.PYLORI ERADICATION: A SINGLE CENTER, PROSPECTIVE, RANDOMIZED TRIAL
EFFECTIVENESS AND SAFETY OFNOVELVONOPRAZAN-BASED REGIMEN FOR H.PYLORI ERADICATION: A SINGLE CENTER, PROSPECTIVE, RANDOMIZED TRIAL

EFFECT OF HELICOBACTER PYLORI VIRULENCE FACTORS ON THE MORPHOLOGICAL CHANGES OF GASTRIC MUCOSA IN PATIENTS WITH CHRONIC GASTRITIS AND THEIR ROLE IN CLARITHROMYCIN PRIMARY RESISTANCE
EFFECT OF HELICOBACTER PYLORI VIRULENCE FACTORS ON THE MORPHOLOGICAL CHANGES OF GASTRIC MUCOSA IN PATIENTS WITH CHRONIC GASTRITIS AND THEIR ROLE IN CLARITHROMYCIN PRIMARY RESISTANCE

PCR IMPROVES DETECTION OF HELICOBACTER PYLORI IN UNSELECTED ADULT PATIENTS UNDERGOING ROUTINE GASTROSCOPY
PCR IMPROVES DETECTION OF HELICOBACTER PYLORI IN UNSELECTED ADULT PATIENTS UNDERGOING ROUTINE GASTROSCOPY

PERNICIOUS ANEMIA AND HELICOBACTER PYLORI INFECTION : AN INTRICATE ASSOCIATION
PERNICIOUS ANEMIA AND HELICOBACTER PYLORI INFECTION : AN INTRICATE ASSOCIATION

ROLE OF THE PROTON PUMP INHIBITORS IN HELICOBACTER PYLORI ERADICATION: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROLE OF THE PROTON PUMP INHIBITORS IN HELICOBACTER PYLORI ERADICATION: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

PROSPECTIVE RANDOMIZED STUDY: HIGH-DOSE AMOXICILLIN DUAL THERAPY VERSUS BISMUTH QUADRUPLE THERAPY FOR HELICOBACTER PYLORI E RADICATION
PROSPECTIVE RANDOMIZED STUDY: HIGH-DOSE AMOXICILLIN DUAL THERAPY VERSUS BISMUTH QUADRUPLE THERAPY FOR HELICOBACTER PYLORI E RADICATION

ERRORS IN EMPIRICAL ANTIBIOTIC THERAPIES FOR HELICOBACTER PYLORI ERADICATION IN 45,778 PATIENTS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ERRORS IN EMPIRICAL ANTIBIOTIC THERAPIES FOR HELICOBACTER PYLORI ERADICATION IN 45,778 PATIENTS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

HOW ARE JAPANESE PATIENTS WITH AUTOIMMUNE GASTRITIS AFFECTED BY H. PYLORI INFECTION?: AN EVALUATION OF SEROLOGICAL, ENDOSCOPIC, AND HISTOLOGICAL FINDINGS
HOW ARE JAPANESE PATIENTS WITH AUTOIMMUNE GASTRITIS AFFECTED BY H. PYLORI INFECTION?: AN EVALUATION OF SEROLOGICAL, ENDOSCOPIC, AND HISTOLOGICAL FINDINGS

DIFFERENCES OF HELICOBACTER PYLORI DIAGNOSTICS AND TREATMENTS IN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
DIFFERENCES OF HELICOBACTER PYLORI DIAGNOSTICS AND TREATMENTS IN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

EFFECTIVENESS AND SAFETY OF HIGH-DOSE DUAL THERAPY: RESULTS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS AND SAFETY OF HIGH-DOSE DUAL THERAPY: RESULTS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

ANTIBIOTIC RESISTANCE OF HELICOBACTER PYLORI IN PRIMARY CARE: AN OBSERVATIONAL COHORT STUDY
ANTIBIOTIC RESISTANCE OF HELICOBACTER PYLORI IN PRIMARY CARE: AN OBSERVATIONAL COHORT STUDY

EFFECT OF METRONIDAZOLE RESISTANCE ON HELICOBACTER PYLORI ERADICATION REGIMENS
EFFECT OF METRONIDAZOLE RESISTANCE ON HELICOBACTER PYLORI ERADICATION REGIMENS

EMPIRIC "THREE-IN-ONE" BISMUTH QUADRUPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION IN THE SECOND LINE: A PROSPECTIVE STUDY IN SOUTHERN ITALY
EMPIRIC "THREE-IN-ONE" BISMUTH QUADRUPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION IN THE SECOND LINE: A PROSPECTIVE STUDY IN SOUTHERN ITALY

ROLE OF COMPLIANCE IN HELICOBACTER PYLORI TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROLE OF COMPLIANCE IN HELICOBACTER PYLORI TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

A PHASE 1, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF VONOPRAZAN- OR ESOMEPRAZOLE-BASED BISMUTH-CONTAINING QUADRUPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION IN CHINA
A PHASE 1, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF VONOPRAZAN- OR ESOMEPRAZOLE-BASED BISMUTH-CONTAINING QUADRUPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION IN CHINA

EVALUATION OF IL-17F A7488G POLYMORPHISM IN HELICOBACTER PYLORI-INFECTED PATIENTS IN QOM-IRAN
EVALUATION OF IL-17F A7488G POLYMORPHISM IN HELICOBACTER PYLORI-INFECTED PATIENTS IN QOM-IRAN

COMPARISON OF THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION REGIMENS BETWEEN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
COMPARISON OF THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION REGIMENS BETWEEN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

PREVALENCE OF HELICOBACTER PYLORI IN OBESE PATIENTS UNDERGOING PREOPERATIVE ENDOSCOPIC EVALUATION FOR BARIATRIC SURGERY: EXPERIENCE FROM A SINGLE CENTER IN NORTHERN ITALY
PREVALENCE OF HELICOBACTER PYLORI IN OBESE PATIENTS UNDERGOING PREOPERATIVE ENDOSCOPIC EVALUATION FOR BARIATRIC SURGERY: EXPERIENCE FROM A SINGLE CENTER IN NORTHERN ITALY

ALTERED GUT MICROBIOTA AND SHORT-CHAIN FATTY ACIDS AFTER VONOPRAZAN-AMOXICILLIN DUAL THERAPY FOR HELICOBACTER PYLORI ERADICATION
ALTERED GUT MICROBIOTA AND SHORT-CHAIN FATTY ACIDS AFTER VONOPRAZAN-AMOXICILLIN DUAL THERAPY FOR HELICOBACTER PYLORI ERADICATION

Item 1 - 20 / 48
1
2 3